Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study

INTRODUCTION: PRI‐002 is an orally available anti–amyloid beta (Aβ) prionic compound developed for direct disassembly of toxic Aβ oligomers relevant to Alzheimer's disease. METHODS: Two placebo‐controlled clinical phase I trials with oral dosing of PRI‐002 were conducted in healthy young subjec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutzsche, Janine, Jürgens, Dagmar, Willuweit, Antje, Adermann, Knut, Fuchs, Carola, Simons, Stefanie, Windisch, Manfred, Hümpel, Michael, Rossberg, Wolfgang, Wolzt, Michael, Willbold, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087413/
https://www.ncbi.nlm.nih.gov/pubmed/32211506
http://dx.doi.org/10.1002/trc2.12001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087413/
https://www.ncbi.nlm.nih.gov/pubmed/32211506
http://dx.doi.org/10.1002/trc2.12001

Ejemplares similares